Cardiff Oncology, Inc. 8-K

What Happened
Cardiff Oncology, Inc. (CRDF) filed a Form 8-K on June 3, 2026 under Item 7.01 (Regulation FD Disclosure) to furnish an investor presentation that reviews its Phase 2 CRDF-004 clinical data and outlines registrational study plans for its drug candidate onvansertib. The presentation is attached as Exhibit 99.1 to the filing. The 8-K notes the exhibit includes forward-looking statements and that the furnished materials are not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Filing date: June 3, 2026; Form 8-K Item 7.01 (Regulation FD Disclosure).
• Subject: Investor presentation reviewing Phase 2 CRDF-004 data and registrational study plans for onvansertib (Exhibit 99.1).
• Legal/filing note: Presentation is furnished (not “filed”) and contains forward‑looking statements.
• Report signed by Mani Mohindru, Interim Chief Executive Officer.

Why It Matters
This disclosure gives investors access to Cardiff’s clinical results and the company’s plan for moving onvansertib into potential registrational (pivotal) studies — key milestones for a clinical-stage biotech. While the filing does not present new financial results, the data and study plans could affect development timelines, regulatory expectations, and future funding or partnership needs. Investors should review the attached presentation for the clinical details and watch for subsequent filings or announcements with formal study designs, timelines, or financial impacts.